天新药业: 第三届董事会第十一次会议决议公告

Core Viewpoint - The board of directors of Jiangxi Tianxin Pharmaceutical Co., Ltd. held its 11th meeting of the third session on August 28, 2025, where several key resolutions were passed, including the approval of the 2025 semi-annual report and the cancellation of the supervisory board [1][2][3][4][5]. Group 1: Board Meeting Details - The meeting was conducted with all 8 directors present, ensuring compliance with relevant laws and regulations [1]. - The board approved the 2025 semi-annual report with unanimous support [2]. - A special report on the use of raised funds for the first half of 2025 was also approved without opposition [2]. Group 2: Governance Changes - The board approved the proposal to cancel the supervisory board and amend the company's articles of association, which will be submitted for shareholder approval [2][3]. - The strategic committee of the board was renamed to include ESG considerations, reflecting a commitment to enhancing the company's governance framework [3]. - Additional amendments to governance systems were approved, with some requiring shareholder review [4]. Group 3: Action Plans and Future Meetings - The board reviewed and approved the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement" action plan for 2025 [4]. - A proposal to convene the first extraordinary general meeting of shareholders in 2025 was also approved [5].